Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 793–796 | Cite as

Utility of day 8 blood tests on platinum plus vinorelbine regimen

  • Rocío Vázquez-SánchezEmail author
  • Raúl Diez-Fernández
  • Santos Enrech-Frances
  • Ana Sánchez-Peña
  • Teresa Molina-García
Short Research Report

Abstract

Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in non-small-cell lung cancer. Some studies have shown that the hemogram on day-8 could be avoided in patients with cisplatin. However, carboplatin had not been studied and is considered to be more myelotoxic than cisplatin. Objective To quantify the incidence of thrombocytopenia, anemia, neutropenia and impaired liver and renal tests on day 8 in patients receiving a doublet protocol including a platinum and vinorelbine. Method The incidence of blood test abnormalities has been quantified in all patients who had received at least one course of cisplatin or carboplatin plus vinorelbine from January 14–December 14. Results Eighty-nine patients and 314 courses on day-8 were evaluated. Moderate or severe hematological toxicity was observed in 5.7 % courses. Dose was skipped in 1.3 % courses related to neutropenia. Renal and liver impairment were not shown. Delayed and reduced doses and early discontinued treatment on day-8 were not caused by blood test abnormalities. Conclusions Blood tests might be spared on day-8 depending on the individual characteristics, above all in patients with carboplatin.

Keywords

Blood test Carboplatin Cisplatin Hematological toxicity Non-small cell lung cancer Vinorelbine 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Castria TB, da Silva EMK, Gois AFT, Riera R. Cisplatin versus carboplatin in combination with third generation drugs for advanced non-small cell lung cancer (Review). Cochrane Database Syst Rev. 2013;8:CD009256.PubMedGoogle Scholar
  4. 4.
    Provencio M, de Las Peñas R, Camps C, Artal A, Massuti B, Cobo M, et al. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: is a hemogram on day 8 essential? Lung Cancer. 2010;68:415–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Provencio M, Sánchez A, Artal A, Sánchez Torres JM, García Gómez R, Constenla M, et al. Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary. Clin Transl Oncol. 2013;15:659–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Cancer Therapy Evaluation Program. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v.4.0. Data files and related documents. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed June 2015.
  7. 7.
    Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung. 2012;190:477–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin based to cisplatin-based chemotherapy in advanced non small cell lung cancer. Lung Cancer. 2007;57:348–58.CrossRefPubMedGoogle Scholar
  9. 9.
    Tan EH, Rolski J, Grodzki T, Schneider CP, Gaztemeier U, Zatloukal P, et al. Global Lung Oncology Branco trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small cell lung cancer. Ann Oncol. 2009;20:1249–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Dygai AM, Zhdanov VV, Zyuz’kov GN, Udut EV, Simanina EV, Gur’yantseva LA, et al. Mechanisms of regulation of hemopoiesis during experimental cytostatic myelosuppression induced by carboplatin. Bull Exp Biol Med. 2007;143:581–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Rocío Vázquez-Sánchez
    • 1
    Email author
  • Raúl Diez-Fernández
    • 1
  • Santos Enrech-Frances
    • 1
  • Ana Sánchez-Peña
    • 1
  • Teresa Molina-García
    • 1
  1. 1.Hospital Universitario de GetafeGetafeSpain

Personalised recommendations